Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 261

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 261
---
 $2.0 million if the Preferred Warrants are exercised. The following table summarizes the shares of our Series A Preferred Stock issued to our related parties:

| Purchasers(1)                          |     | Shares of 
 Series A  
 Preferred 
 Stock     |       |     | Total    
 Purchase 
 Price    |           |
|:---------------------------------------|:----|:----------|------:|:----|:---------|----------:|
| Daniel Corey(2)                        |     |           |   150 |     | $        |   150,000 |
| Atwood-Edminster Trust dtd 4-2-2000(3) |     |           | 1,002 |     | $        | 1,002,000 |
| Chris Ehrlich(4)                       |     |           |   275 |     | $        |   275,000 |
| Phoenix Biotech Sponsor, LLC(5)        |     |           | 1,380 |     | $        | 1,380,000 |

| (1) | Additional details regarding these stockholders and their equity                     
 holdings are included in this prospectus under the section “Principal Stockholders.” |

| (2) | Daniel Corey served as the Chief Technology Officer and a member                                                                   
 of the board of directors from February 2024 to September 2024, and previously served as Chief Executive Officer, Chief Scientific 
 Officer, and a member of the board of directors of Legacy CERo until the closing of the Business Combination in February 2024.     |

| (3) | Brian G. Atwood served as Chairman and Chief Executive                                                                                
 Officer from February 2024 to September 2024, and previously served as Chairman of PBAX until the closing of the Business Combination 
 in February 2024 Mr. Atwood is a member of the board of directors and serves as a trustee of Atwood-Edminster Trust dtd 4-2-2000.     |

| (4) | Chris Ehrlich has served as the Chairman and Chief Executive                                                             
 Officer since December 2024, and previously served as (i) interim Chairman and Chief Executive Officer from October 2024 
 to November 2024, (ii) Vice Chairman of the board of directors from February 2024 to September 2024, and (iii) the       
 Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024.                          |

| (